RxDoctor Payments Data

Igor Westra, MD

Retina Specialist · Wilmington, NCNPI 1679543870

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Notal Vision, Inc. at 52.9% of the total. Reporting peaked in 2022 at $1,757 and has fallen 96.5% since, to $62 in 2025. That places this record below the midpoint for retina specialist clinicians in NC, where the typical reported total is $3,753.

$2,958in general payments, 2019–2025

Across 59 payments — averaging $50.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Notal Vision, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$680
  • Genentech USA, Inc.$227
  • Bausch & Lomb Americas Inc.$134
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$127
  • Astellas Pharma US Inc$103
  • plus $122 from 3 others
$2,370in research payments, 2019–2025

Across 67 payments — averaging $35.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$2K

What the payments were for

  • Speaking & faculty fees$1,54152%
  • Food & beverage$1,41748%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,958 in reported general payments places this provider in the 45th percentile of 34 retina specialist providers in North Carolina.

See all retina specialist providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,945,178
Medicare patients
918
Services billed
24,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$45,369
ProlensaBromfenac Sodium23$8,237
Bromfenac Sodium20$5,296
Cyclosporine30$4,596
Prednisolone Acetate39$3,073
Atropine Sulfate14$810
Ketorolac Tromethamine23$491
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha19$251
Timolol Maleate19$188
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$116
Latanoprost14$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$29$45,36948 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$127$8,23723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 34 retina specialist providers in North Carolina.

Other retina specialist in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →